Results 21 to 30 of about 652,488 (245)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

Leukemia Research Reports, 2022
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of
Suheil Albert Atallah-Yunes, Michael J. Robertson   +1 more
doaj   +1 more source

Monoclonal antibodies: their place in applied medicine and their role in the newest infectious disease – history, present, and future. Literature review [PDF]

Pharmacia
Monoclonal antibodies (mAbs) are immunoglobulins with practically absolute specificity (monospecificity) for a particular antigen (epitope). Over the past three decades, monoclonal antibodies have undergone a remarkable transformation, evolving from ...
Petar Yordanov Atanasov, Maria Georgieva Moneva-Sakelarieva, Yozlem Ali Kobakova, Stefka Achkova Ivanova, Maria Vakrilova Becheva, Angelina Georgieva Kirkova-Bogdanova, Maria Sevdelinova Chaneva, Ventseslava Petrova Atanasova, Radoslav Fedeev Todorov, Nikolay Zarkov Bashev, Ismail Elhanov Bashov, Adel Habib Ibrahim   +11 more
doaj   +3 more sources

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

38227 Specific and highly potent human monoclonal antibodies against SARS-CoV-2

Journal of Clinical and Translational Science, 2021
IMPACT: We devised a new method to produce highly potent SARS-CoV2-specific that can be used to treat severely ill patients with Covid-19. OBJECTIVES/GOALS: Neutralizing antibodies against SARS-CoV-2 are thought to offer the most immediate and effective ...
Mayara Garcia de Mattos Barbosa, Hui Liu, Daniel Huynh, Jeffrey L. Platt, Marilia Cascalho   +4 more
doaj   +1 more source

Circulating histones as clinical biomarkers in critically ill conditions

FEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez, Juan Carlos Ruiz‐Rodríguez, Ricard Ferrer, Raquel Durá, Antonio Artigas, Iván Bajaña, David Bolado López de Andujar, Irene Cánovas‐Cervera, Adrián Ceccato, Luis Chiscano‐Camón, Elena Climent‐Martinez, Georgia García Fernández, Gemma Goma, Verónica Monforte, Beatriz Quevedo‐Sánchez, Adolf Ruiz‐Sanmartín, Antonio Sierra‐Rivera, Nieves Carbonell Monleón   +17 more
wiley   +1 more source

Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactors

Frontiers in Bioengineering and Biotechnology
The Chinese hamster ovarian (CHO) cells serve as a common choice in biopharmaceutical production, traditionally cultivated in stirred tank bioreactors (STRs).
Xuekun Wang, Xuekun Wang, Jin Xu, Jin Xu, Jin Xu, Qingcheng Guo, Qingcheng Guo, Qingcheng Guo, Qingcheng Guo, Zhenhua Li, Zhenhua Li, Zhenhua Li, Jiawei Cao, Jiawei Cao, Jiawei Cao, Rongrong Fu, Rongrong Fu, Mengjiao Xu, Mengjiao Xu, Xiang Zhao, Xiang Zhao, Fugui Wang, Fugui Wang, Xinmeng Zhang, Taimin Dong, Xu Li, Weizhu Qian, Weizhu Qian, Weizhu Qian, Shen Hou, Shen Hou, Shen Hou, Lusha Ji, Lusha Ji, Lusha Ji, Dapeng Zhang, Dapeng Zhang, Dapeng Zhang, Huaizu Guo, Huaizu Guo, Huaizu Guo, Huaizu Guo   +41 more
doaj   +1 more source

Monoclonal Antibodies as Immune Modulators for Cancer Therapy

Canadian Journal of Infectious Diseases, 1992
Monoclonal antibodies may modulate immune and/or biological responses alone, or as carriers of specific agents. Monoclonal antibodies directed against tumours may be indirectly cytotoxic by modulation of antibody-dependent, cell-mediated cytotoxicity or ...
Robert O Dillman
doaj   +1 more source

Single‐cell insights into the role of T cells in B‐cell malignancies

FEBS Letters, EarlyView.
Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley   +1 more source

Methodological validation study of nrCE-SDS for monoclonal antibodies

生物医学转化
Objective To perform methodological validation of non-reduced capillary electrophoresis-sodium dodecyl sulfate (nrCE-SDS) for monoclonal antibodies, providing a reference for the methodological validation of corresponding quality control methods in the ...
Xu Gangling, Ni Yongbo, Wu Gang, Fu Zhihao, Yu Chuanfei, Wang Lan   +5 more
doaj   +1 more source

PCSK9 monoclonal antibodies: An overview

Heart Views, 2020
PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs.
Rasha Kaddoura, Bassant Orabi, Amar M Salam   +2 more
doaj   +1 more source